CRY2 and breast carcinoma: As for CRY2, it can exert an anti-proliferative effect on breast cancer cells because it may bind and inhibit the p65/p50 complex, thus inhibiting the nuclear factor-κB (NF-κB) pathway, but its acetylation in breast cancer impairs this function (30), the exact mechanism has yet to be studied.